Business
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week...
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting \n BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced two new abstracts featuring new clinical data on the Company’s two product candidates, MAU868 in kidney transplant and atacicept in immunoglobulin A nephropathy (IgAN). These data are to be presented in oral and poster sessions, respectively, at the American Society of Nephrology Kidney Week 2022 Annual Meeting, being held November 3-6, 2022 in Orlando, Florida. The oral presentation on MAU868 includes final results from the Phase 2 clinical trial of MAU868 versus placebo to treat BKV in kidney transplant patients. The poster presentation on atacicept includes a new analysis of previously presented clinical data from the Phase 2a JANUS clinical trial evaluating atacicept in patients with IgAN. Details of the presentations are as follows: Title: A Randomized Phase 2 Study of MAU868 vs. Placebo to Treat BK Viremia in Kidney Transplant RecipientsDate and Time: November 5, 2022, 4:48 PM ETPresentation: OralSession: Transplantation: Clinical Outcomes and BiomarkersAbstract Number: SA-OR43Location: W240, Orange County Convention Center, West BuildingPresenter: Stanley C. Jordan, M.D., FASN, FAST, Director of Nephrology & Transplant Immunology, Cedars-Sinai Medical Center, Professor of Pediatrics and Medicine at the David Geffen School of Medicine at University of California, Los Angeles Title: Atacicept Reduces Serum Immune Complex Levels in Patients with Immunoglobulin A Nephropathy (IgAN)Date and Time: November 5, 2022, 10:00 AM – 12:00 PM ETPresentation: PosterSession: Glomerular Diseases: IgA and Complement-Mediated GNAbstract Number: SA-PO655Location: Exhibit Hall, Orange County Convention Center, West BuildingPresenter: Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, U.K. About MAU868MAU868, a first-in-class monoclonal antibody, has the potential to neutralize in...